AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 212 min read$GKOS

Thurman Alex R. sold $1.6M of GKOS

Thurman Alex R. (SVP & CHIEF FINANCIAL OFFICER) sold 10,000 shares of GLAUKOS Corp (GKOS) at $160.00 ($1.60M total) on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thurman Alex R.
Published Jul 21, 2026, 8:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 21, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$GKOS
Neutral
medium confidence
Mentioned
$GKOS
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider confidence, but the pre-arranged nature reduces informational content versus unscheduled sales.

02

Market read

A CFO 10b5-1 sale of about $1.6M is disclosed, which is usually low-signal for fundamentals.

03

What to watch

Insider sales under 10b5-1 often occur regardless of company outlook; without accompanying buys or changes in guidance, the trading signal is weak.

Relevance 5/10Novelty 3/10Timing: Filed 2026-07-21 after-hours/late session, with sale dated 2026-07-16.

Background

This is an SEC Form 4 insider transaction by GKOS’s CFO, reported as an open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$GKOSNeutralMedium confidence
Context

Form 4 shows GKOS CFO Thurman Alex R. sold 10,000 shares on 2026-07-16 under a pre-arranged 10b5-1 plan for about $1.6M.

Expected impact

Likely minimal price impact; any reaction should fade unless accompanied by other negative company news.

Evidence & confidence

The filing is a primary-source insider transaction, but it is explicitly under a pre-arranged 10b5-1 plan and does not disclose new fundamentals.

Market effects

Sector

No clear sector read-through from a single CFO 10b5-1 sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be purely liquidity-driven under a scheduled 10b5-1 plan, so it should not be interpreted as a negative view on GKOS prospects.

Key entities

  • issuer
    GLAUKOS Corp

    Company whose insider transaction is disclosed on Form 4 (GKOS).

  • insider
    Thurman Alex R.

    SVP and Chief Financial Officer who sold 10,000 shares.

  • trading mechanism
    10b5-1 plan

    Pre-arranged plan that schedules trades, typically lowering interpretive value.

Read at source← All news

Related articles

AUG 8
$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.

aol.com7 min
JUL 30
$GKOSHighAI 9/10

Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up

Glaukos (GKOS) reported Q2 2026 adjusted loss of 14 cents per share, better than the Zacks Consensus loss of 28 cents. Revenue rose to $185.6 million, up 50% year over year, beating the consensus by 24.1%. Management raised 2026 net sales guidance to $680 million to $700 million. Shares rose 9.8% in after-hours.

tradingview.com6 min
JUL 30
$GKOSMed

Glaukos Q2 Earnings Call Highlights

Glaukos (NYSE:GKOS) reported Q2 updates on iDose TR, including acceleration across Medicare Administrative Contractor regions and no material demand pull-forward from proposed LCDs. International glaucoma revenue rose to $36.6M (+17%); corneal health revenue rose 48% to $30.4M with ~$11M Epioxa. Gross margin was ~85%. Full-year targets: gross margin 84% to 86%, corneal health growth ~20%.

finance.yahoo.com4 min
JUL 29
$GKOSMedAI 8/10

GLAUKOS Corp (GKOS): Results of Operations and Financial Condition

GLAUKOS Corp (GKOS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 gkos-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 JULY 29, 2026 GLAUKOS CORPORATION (NYSE: GKOS) SECOND QUARTER 2026 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designe

SEC EDGAR 8-K6 min
JUL 29
$GKOSMed

Midday Stock Roundup: Glaukos Rises

A midday roundup highlights multiple movers. V.F. Corp. (VFC) fell 17% to $15.24 after lower first-quarter revenue tied to weakness in Vans and CFO Paul Vogel leaving. Envista (NVST) rose 6.2% to $28.63 ahead of an Sept. 17 investor day. Glaukos (GKOS) gained 7.9% to $159.25 after completing patient enrollment in a 510(k) glaucoma study.

ocbj.com3 min